Generation of tumor-targeted antibody-CpG conjugates

Journal of Immunological Methods

Volumn 389, Issue 1-2, 2013, Pages 45-51

  Li, Zhongjun ^a,b   Jang, Julie K ^a   Lechner, Melissa G ^a   Hu, Peisheng ^a   Khawli, Leslie ^a,c   Scannell, Christopher A ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c GENENTECH INC   (United States)

Author keywords

Antibody; CpG oligodeoxynucleotides; Immunoconjugates; Immunotherapy; Rituximab; Trastuzumab

Indexed keywords

ANTIBODY CONJUGATE; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 6; LIGAND; RITUXIMAB; RITUXIMAB CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; TRASTUZUMAB; TRASTUZUMAB CPG OLIGODEOXYNUCLEOTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CONJUGATION; DRUG TARGETING; FEASIBILITY STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOSTIMULATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CELL LINE, TUMOR; HUMANS; IMMUNOCONJUGATES; JURKAT CELLS; MICE; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84873745166     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.12.009     Document Type: Article

References (22)

1. Amos S.M., Pegram H.J., Westwood J.A., John L.B., Devaud C., Clarke C.J., Restifo N.P., Smyth M.J., Darcy P.K., Kershaw M.H. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol. Immunother. 2011, 60:671.
2. Ballas Z.K. Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol. Res. 2007, 39:15.
3. Buhtoiarov I.N., Sondel P.M., Wigginton J.M., Buhtoiarova T.N., Yanke E.M., Mahvi D.A., Rakhmilevich A.L. Anti-tumor synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumor associated macrophages. Immunology 2011, 132:226.
4. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6:443.
5. Dalpke A.H., Zimmermann S., Albrecht I., Heeg K. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology 2002, 106:102.
6. Deonarain M.P. Recombinant antibodies for cancer therapy. Expert Opin. Biol. Ther. 2008, 8:1123.
7. Jakob T., Walker P.S., Krieg A.M., von Stebut E., Udey M.C., Vogel J.C. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int. Arch. Allergy Immunol. 1999, 118:457.
8. Kandimalla E.R., Bhagat L., Yu D., Cong Y., Tang J., Agrawal S. Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug. Chem. 2002, 13:966.
9. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709.
10. Krieg A.M., Efler S.M., Wittpoth M., Al Adhami M.J., Davis H.L. Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J. Immunother. 2004, 27:460.
11. Krug A., Rothenfusser S., Hornung V., Jahrsdörfer B., Blackwell S., Ballas Z.K., Endres S., Krieg A.M., Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur. J. Immunol. 2001, 31:2154.
12. Lechner M.G., Russell S.M., Bass R.S., Epstein A.L. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy 2011, 3:1317.
13. Lim S.H., Beers S.A., French R.R., Johnson P.W., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95:135.
14. Sanjuan M.A., Rao N., Lai K.T., Gu Y., Sun S., Fuchs A., Fung-Leung W.P., Colonna M., Karlsson L. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion. J. Cell Biol. 2006, 172:1057.
15. Schettini J., Kidiyoor A., Besmer D.M., Tinder T.L., Roy L.D., Lustgarten J., Gendler S.J., Mukherjee P. Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol. Immunother. 2012, 61:2055.
16. Sharma S., Karakousis C.P., Takita H., Shin K., Brooks S.P. Intratumoral injections of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors. Biotechnol. Lett. 2003, 25:149.
17. Shirota Y., Shirota H., Klinman D.M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J. Immunol. 2012, 188:1592.
18. Simeone E., Ascierto P.A. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J. Immunotoxicol. 2012, 9:241.
19. Steiner M., Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin. Cancer Res. 2011, 17:6406.
20. Weiner L.M., Murray J.C., Shuptrine C.W. Antibody-based immunotherapy of cancer. Cell 2012, 148:1081.
21. Zhu P., Liu X., Treml L.S., Cancro M.P., Freedman B.D. Mechanism and regulatory function of CpG signaling via scavenger receptor B1 in primary B cells. J. Biol. Chem. 2009, 284:22878.
22. Zoglmeier C., Bauer H., Nörenberg D., Wedekind G., Bittner P., Sandholzer N., Rapp M., Anz D., Endres S., Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 2011, 17:1765.